NF‐κB/NKILA signaling modulates the anti‐cancerous effects of EZH2 inhibition

A wealth of evidence supports the broad therapeutic potential of NF‐κB and EZH2 inhibitors as adjuvants for breast cancer treatment. We contribute to this knowledge by elucidating, for the first time, unique regulatory crosstalk between EZH2, NF‐κB and the NF‐κB interacting long non‐coding RNA (NKIL...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Suzann, Chan, Westin K., Oman, Andrew, Basile, Dominic P., Alvira, Cristina M., Buxton, Iain L.O., Iosef, Cristiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714229/
https://www.ncbi.nlm.nih.gov/pubmed/31282094
http://dx.doi.org/10.1111/jcmm.14500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714229/
https://www.ncbi.nlm.nih.gov/pubmed/31282094
http://dx.doi.org/10.1111/jcmm.14500

Ejemplares similares